2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5212 CD64, marker of hematopoietic maturation, is highly associated with KMT2-r AML and favorable outcome

Rhonda E. Ries, MA, Maria Pardo2, Fangyan Dai3, Andrew J. Menssen, Ph.D., HCLD(ABB)4, Jim Wang5, Todd A. Alonzo, PhD6, Jack H. Peplinski, MSc7, Danielle C. Kirkey, MD8, Chad A. Hudson, MD, Ph.D9, Katherine Tarlock I, MD10, Todd Cooper I, DO11, Michael Loken, PhD12, Soheil Meshinchi, MD, PhD13
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 Hematologics, Inc., Seattle, Washington, United States
3 Hematologics, Inc., Seattle, Washington, United States
4 Hematologics, Inc., Seattle, Washington, United States
5 Children's Oncology Group, Arcadia, California, United States
6 Children's Oncology Group, Arcadia, California, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 Hematologics, Inc., Seattle, Washington, United States
10 Seattle Children's Hospital, Seattle, Washington, United States
11 Seattle Children's Hospital, Seattle, Washington, United States
12 Hematologics, Inc., Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States

CD64, a membrane glycoprotein Fc receptor expressed during hematopoietic maturation, is a known marker of monocytic differentiation.  This cell surface marker has been implicated in monocytic leukemia stem cells in patients who are refractory to Venetoclax (PMID: 37358260).  Here we describe CD64’s expression in successive Children’s Oncology Group (COG) trials and correlate expression with molecular features and clinical outcome in AML in children and young adults. 

Using multidimensional quantitative flow cytometry, we assessed CD64 expression across 1633 patients in COG AAML1031 (N=866) and in COG AAML1831 (N=767). All samples were processed at Hematologics, Inc. (Seattle, WA) and Mean Fluorescence Intensity (MFI) determined for each patient. CD64 Log2 MFI ranged from 1.17-11.91 and initial evaluation revealed a distinct bimodal distribution of expression.  Gaussian mixture model (GMM) was applied and optimal cutpoint of 6.32 Log2 MFI (corresponding to 2,000 molecules of CD64) differentiated the high CD64 (CD64Hi) expression (N=490) from those with lower expression (CD64low; N=1143).  Overall, CD64 expression was present in 30% of patients in the cohort. 

We assessed CD64 expression across common cyto/molecular subtypes and its association with clinical characteristics and outcome.  CD64 expression was substantially higher in KMT2A-r AML (Median Log2 MFI 8.6) where 86% of KMT2A-r patients had CD64Hi disease. In contrast, the median Log2 MFI of other fusion subtypes were much lower: CBFA2T3-GLIS2 (Log2 MFI 2.0), NUP98-KDM5A (Log2 MFI 3.0), RUNX1-RUNX1T1 (Log2 MFI 3.7), CBFB-MYH11 (Log2 MFI 4.7), and NUP98-NSD1 Log2 MFI 5.5).  The non-KMT2A-r fusion patients were predominantly CD64low where only 11% had CD64Hi expression.

With the exception of NPM1, patients with common mutations were overwhelmingly CD64low.   NPM1 positive patients had a median Log2 MFI 5.0 (range 2.5-9.9) and 39% of cases were CD64Hi.  In patients with FLT3-ITD or CEBPA, CD64Hi expression was present in 17% and 6% respectively.

We evaluated the clinical response and outcomes for patients based on CD64 expression threshold of 6.32 as defined by the GMM statistical model.   This analysis was limited to KMT2A-r and NPM1 positive AML patients, the only two cohorts with adequate numbers of CD64low and CD64Hi for meaningful comparison. 

In COG AAML1031, outcomes for 190 KMT2A-r patients were determined in CD64low (n=27) vs. CD64Hi (n=163) using the Kaplan-Meier log-rank test.  At 3 years from diagnosis, event-free (EFS) was 15% for CD64low vs. 37% for CD64Hi expressors (p=0.001) with a corresponding overall survival (OS) of 22% vs. 61% (p<0.001).  We further evaluated the significance of CD64 expression in patients with standard risk KMT2A-r (KMT2A-SR) AML as defined by fusion partners.  Within KMT2A-SR patients, EFS at 3 years from diagnosis for those with CD64low vs. CD64Hi was 6% vs. 44% (p<0.001) with a corresponding OS of 13% vs. 73% (p<0.001).  Remarkably, KMT2A-MLLT3 CD64low expressors had the lowest EFS and OS: 3-year EFS was 0% vs. 43.1% (p<0.001) while OS was 0% vs. 70.4% (p<0.001). 

These observations were validated in COG AAML1831.  In this study, KMT2A-r patients with CD64low vs. CD64Hi expression had a 3-year EFS of 14% vs. 54% (p=0.002) with a corresponding OS of 39% and 74% (p=0.009), respectively.  For the KMT2A-SR group, 3-year EFS and OS both remained significant where CD64low patients had an EFS of 17% vs. 58% for CD64Hi (p=0.008); OS was 28% vs. 78% (p=0.027). 

In COG AAML1031, 64 NPM1 positive patients were compared; CD64low (n=39) vs. CD64Hi (n=25).  CD64low NPM1-positive patients had a 3-year EFS of 65% vs. 79% in CD64Hi patients (p=0.239); a finding that was validated in COG AAML1831 with corresponding EFS of 74% and 92% in the CD64low vs. CD64Hi patients (p=0.38). 

Here we demonstrate that evaluation of immunophenotype at diagnosis can better risk classify patients.  In childhood AML 30% of patients express CD64 while 70% lack expression.  The KMT2A-r subtype comprises the largest proportion of CD64Hi expressors, however CD64low patients have worse EFS and OS, particularly KMT2A-MLLT3 which represent roughly 40% of the KMT2A-r subtype. Identification of this high-risk subgroup using quantitative multidimensional flow cytometry at diagnosis could potentiate therapeutic intervention, particularly for the non-high risk KMT2A-MLLT3 cohort.

Rhonda E. Ries, MA: No relevant conflicts of interest to declare.